Oncolytic Measles Virus Retargeting by Ligand Display
Oncolytic Measles Virus Retargeting by Ligand Display
复制标题
DOI：
10.1007/978-1-61779-340-0_11
复制
发表时间：
2012-01-01
期刊：
影响因子：
--
通讯作者：
Galanis, Evanthia
中科院分区：
文献类型：
--
作者：
Msaouel, Pavlos;Iankov, Ianko D.;Galanis, Evanthia
尽管近年来取得了重大进展，但转移性恶性肿瘤的治疗仍然是一个重大挑战。迫切需要开发新的治疗方法。病毒治疗方法具有相当大的潜力，其中麻疹病毒（MV）疫苗株已成为一个有前途的溶瘤平台。来自Edmonston疫苗谱系的重靶向MV菌株（MV- edm）对表达受体的肿瘤细胞的抗肿瘤效果与未经修饰的菌株相当，治疗指数更高。在这里，我们描述了完全重靶向的MV-Edm衍生物的构建、修复、扩增和滴定，这些衍生物在病毒表面显示肿瘤特异性受体结合配体，结合H蛋白CD46和SLAM进入消融突变。
Despite significant advances in recent years, treatment of metastatic malignancies remains a significant challenge. There is an urgent need for development of novel therapeutic approaches. Virotherapy approaches have considerable potential, and among them measles virus (MV) vaccine strains have emerged as a promising oncolytic platform. Retargeted MV strains deriving from the Edmonston vaccine lineage (MV-Edm) have shown comparable antitumor efficacy to unmodified strains against receptor expressing tumor cells with improved therapeutic index. Here, we describe the construction, rescue, amplification, and titration of fully retargeted MV-Edm derivatives displaying tumor specific receptor binding ligands on the viral surface in combination with H protein CD46 and SLAM entry ablating mutations.